Northern Light
Eastern Maine Medical Center

Cancer Research Clinical Trials

Updated: 11/4/26

BioBanking

A212102 **NCT05334069**		Blinded Reference Set for Multicancer Early Detection Blood Tests
A151804 **NCT04242095**		Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

BREAST - Adjuvant HER2+

A012303 **NCT06325683**		ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade

BREAST - ER+/HER2-

EA1242 **NCT07391774**		A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS less than or equal to 25 (RxFINE-Low)

Metastatic

ASCO CDK Study **NCT06377852**		Comparing Oral Drug Dosing Strategies in Older Patients With Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Triple Negative

DFCI 18-617 **NCT# N/A**		A Prospective Registry to Cure Triple-Negative Breast Cancer in Patients With Early-Stage or Newly Diagnosed Metastatic Disease: The TNBC Registry
DFCI 20-166 **NCT04468061**		Saci-IO TNBC: Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC)

Children's Oncology Group Registry

APEC14B1 **NCT02402244**	**Patients 25 years old and younger**	Project EveryChild: A Registry, Eligibility Screening, Biology and Outcome Registry

ComboMATCH Trials

EAY191 **NCT05564377**		Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-N5 **NCT06126276**		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

Germ Cell

AGCT1531 **NCT03067181**	**Patients <50 years of age**	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standar Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532 **NCT02585697**	**Patients </=45 years of age**	A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

GYN

NRG-GY035 **NCT07198074**		A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer

Head & Neck

NRG-HN015 **NCT07195734**		A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)
NRG-HN016 **NCT07441681**		Radiotherapy with Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin: A Pragmatic Phase III Randomized Trial (CONCISE)

Lung Cancer - Adjuvant

A081801 **NCT04267848**		Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Lung Cancer - 1st Line Metastatic

LUNGMAP **NCT03851445**		A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
SWOG S1900G **NCT05642572**		A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1900K **NCT06031688**		A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
SWOG S1800E **NCT06616584**		A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Lung Cancer - 3B/C and Metastatic

EA5221 **NCT06096844**		A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

Lymphoma

AHOD2131 **NCT05675410**	**Patients <60 years of age**	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

MCGI

MCGI 2.0		The Maine Cancer Genomics Initiative (MCGI) 2.0: A Study of Oncology Clinician and Patient Experiences with Clinical Genomics in Northern New England

Multiple Myeloma

PrE1005 **NCT07285239**		Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination with Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Prostate

SWOG S1802 **NCT03678025**		Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Rare Tumors

TAPUR **NCT02693535**		The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Renal Cell

A032201 **NCT06661720**		Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer (STRIKE)

Urothelial

A032103 **NCT05987241**		MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer